Steffen-Sebastian Bolz, Aphaia Pharma CSO
Aphaia hits primary endpoint with oral glucose drug in mid-stage prediabetes trial
The idea behind Aphaia Pharma is to treat metabolic disease early enough that patients don’t progress to a type 2 diabetes diagnosis.
The company is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
